Home›Companies›Biotech & Pharma›LurexBio

Lurex Bio, Inc.

Develops a platform intended to help the immune system recognize tumors in cancer patients.

Updated Nov 9, 2026·Latest SEC filing Aug 31, 2026·Suggest an edit

About LurexBio

LurexBio is a private company based in Fort Lauderdale, Florida, incorporated in 2025 in Delaware. It has reported $150,000 raised in one offering on Form D since February 2026. Its chief executive is George Sens.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jan 22, 2026Feb 5, 2026amended Aug 31, 2026$150,000target not set3$50,000Equity, DebtRule 506(c)Form D/A ↗1 earlier filing

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on LurexBio's Form D filed Aug 31, 2026.

MS
Mark Shumate
VP, Capital & Partnerships, director
GS
George Sens
Chief Executive Officer
James Clark
James Clark
Founder & Inventor
HI
Horace Lanier, III
Chief Operating Officer and Secretary, director

Sources

  1. SECLUREX BIO, INC Form D, filed Feb 5, 2026
  2. SECLUREX BIO, INC filing history
  3. CompanyLurexBio company